Notably, the down-regulation of MMPs observed after AdoMet treatment as well as the AdoMet-induced increased levels of E-cadherin, and decreased levels of N-cadherin, vimentin, β-catenin, SMAD-2,3 and their phosphorylated forms were all enhanced by the combined treatment of AdoMet with miR-34c or miR-449a providing convincing evidence that AdoMet exhibited its antitumor activity in MDA-MB-231 and MDA-MB-468 cells through up-regulation of these tumor suppressive miRNAs. This evidence concerns the gene CDH1 and neoplasm.